VBIO
Valion Bio, Inc.Company Information
- Company Name
- Valion Bio, Inc.
- CIK
- CIK0001787740
- Category
- <br>Emerging growth company
- Ticker: Exchange
- VBIO: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- VBIO
SEC filing data through
Insider Sentiment
- Last purchase
- 2026-04-15
- Last sale
- —
- Shares purchased (TTM)
- 29,000
- Shares sold (TTM)
- 0
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 347,432
- Shares outstanding
- 3,379,997
- Ownership
- 10.28%
Earnings Market Reaction
- Filing date
- 2026-08-14
- Price on filing date
- —
- 1-month reaction
- -41.99%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 2 | 7 | 13 | 3 | 1 | 1 | 2 | 2 | 4 | 2 | 3 | 5 | ||||||
| Accounts Receivable Net Current | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Prepaid Expense And Other Assets Current | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Inventory Net | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | ||||||
| Assets Of Disposal Group Including Discontinued Operation Current | 0 | 0 | 0 | - | - | - | 0 | - | - | - | - | - | ||||||
| Assets Current | 3 | 9 | 13 | 4 | 2 | 1 | 3 | 3 | 5 | 3 | 5 | 6 | ||||||
| Property Plant And Equipment Net | 12 | 13 | 13 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Deferred Costs | 1 | 1 | 0 | 0 | - | - | 0 | - | - | 0 | 0 | - | ||||||
| Intangible Assets Net Excluding Goodwill | 2 | 2 | 2 | 2 | - | - | 0 | - | - | - | - | - | ||||||
| Operating Lease Right Of Use Asset | 10 | 10 | - | - | - | - | - | - | - | 0 | 0 | 0 | ||||||
| Goodwill | 3 | 3 | 3 | - | - | - | 0 | - | - | - | - | - | ||||||
| Restricted Cash Noncurrent | 0 | 0 | - | - | 0 | 0 | - | - | - | - | - | - | ||||||
| Other Assets Noncurrent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | - | 0 | 0 | 0 | ||||||
| Disposal Group Including Discontinued Operation Assets Noncurrent | - | - | 0 | - | - | - | 0 | - | - | - | - | - | ||||||
| Assets | 32 | 38 | 32 | 6 | 5 | 4 | 3 | 3 | 5 | 3 | 5 | 7 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | ||||||
| Other Accrued Liabilities Current | 2 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Operating Lease Liability Current | 1 | 0 | - | - | - | - | - | - | - | 0 | 0 | 0 | ||||||
| Liabilities Of Disposal Group Including Discontinued Operation Current | 0 | 0 | 0 | - | - | - | 0 | - | - | - | - | - | ||||||
| Liabilities Current | 3 | 3 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | ||||||
| Convertible Debt Noncurrent | 7 | 7 | 6 | - | - | - | 0 | - | - | - | - | - | ||||||
| Derivative Liabilities Noncurrent | 0 | 0 | 0 | - | - | - | 0 | - | - | - | - | - | ||||||
| Operating Lease Liability Noncurrent | 9 | 10 | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 | ||||||
| Other Liabilities Noncurrent | 0 | 0 | 0 | - | - | - | 0 | - | - | - | - | - | ||||||
| Liabilities Of Disposal Group Including Discontinued Operation Noncurrent | - | - | 0 | - | - | - | 0 | - | - | - | - | - | ||||||
| Liabilities | 21 | 20 | 7 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 2 | 1 | ||||||
Stockholders Equity | ||||||||||||||||||
| Preferred Stock Value | 0 | 0 | 0 | 0 | - | - | 0 | - | - | - | - | - | ||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital | 71 | 70 | 69 | 55 | 51 | 48 | 46 | 45 | 45 | 42 | 41 | 41 | ||||||
| Retained Earnings Accumulated Deficit | -67 | -59 | -53 | -50 | -47 | -45 | -44 | -42 | -41 | -39 | -38 | -36 | ||||||
| Stockholders Equity | 4 | 11 | 17 | 6 | 4 | 3 | 3 | 3 | 4 | 2 | 4 | 6 | ||||||
| Liabilities And Stockholders Equity | 32 | 38 | 32 | 6 | 5 | 4 | 3 | 3 | 5 | 3 | 5 | 7 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | ||||||
| Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | ||||||
| Common Stock Shares Issued | 4 | 3 | 3 | 2 | 1 | 1 | 1 | 6 | 6 | 1 | 0 | 1 | ||||||
| Shares Outstanding | 4 | 3 | 3 | 2 | 1 | 1 | 1 | 6 | 6 | 1 | 0 | 1 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialValion Bio, Inc. (VBIO) — SEC Financial Statements & Analysis
Valion Bio, Inc. (VBIO) is a pharmaceutical preparations company, incorporated in DE. Valion Bio, Inc. trades on Nasdaq as: VBIO. Valion Bio, Inc. (VBIO)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-14. Based on that filing, Valion Bio, Inc. carries a market cap of $43.94M, a P/E ratio of -2.34x, a P/B ratio of 10.35x, a P/S ratio of 300.96x, an enterprise value of $48.85M, and an EV/EBITDA multiple of -2.95x. On profitability, it posts a gross margin of -58.09%, an operating margin of -11576.03%, a net margin of -12842.47%, a Return on Equity (ROE) of -472.71%, a Return on Assets (ROA) of -101.40%, and a Return on Invested Capital (ROIC) of -289.57%. Per share, it reports EPS of $-5.55, diluted EPS of $-7.20, free cash flow per share of $-4.34, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of -68.40% year-over-year, net income growth of 195.69% year-over-year, and EPS growth of -22.90% year-over-year. On the balance sheet, it maintains a current ratio of 1.11x, a quick ratio of 0.69x, working capital of $336.00K, a debt-to-equity ratio of 4.85x, a debt ratio of 0.63, an interest coverage ratio of -12.62x, free cash flow of $-14.67M (TTM), and net debt of $4.91M. Figures sourced from SEC EDGAR.
- Market Cap
- $43.94M
- P/E TTM
- -2.34x
- EPS TTM
- $-5.55
- P/B TTM
- 10.35x
- ROE TTM
- -472.71%
- ROA TTM
- -101.40%
- Debt To Equity
- 4.85x
- Free Cash Flow TTM
- $-14.67M
- Net Revenue TTM Growth 1Y
- -68.40%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Valion Bio, Inc. in?
Valion Bio, Inc. (VBIO) operates in the Pharmaceutical Preparations industry.
What exchange does VBIO trade on?
Valion Bio, Inc. (VBIO) trades on the Nasdaq.
Where is Valion Bio, Inc. incorporated?
Valion Bio, Inc. is incorporated in DE.
When was Valion Bio, Inc. (VBIO)'s most recent SEC filing?
Valion Bio, Inc. (VBIO)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-14.
What is VBIO's market cap?
Valion Bio, Inc. (VBIO) has a market capitalization of $43.94M as of 2026-06-30.
What is VBIO's EPS (earnings per share)?
Valion Bio, Inc. (VBIO)'s trailing twelve month EPS is $-5.55 as of 2026-06-30.
What is VBIO's ROE (return on equity)?
Valion Bio, Inc. (VBIO)'s trailing twelve month Return on Equity (ROE) is -472.71% as of 2026-06-30.
What is VBIO's ROA (return on assets)?
Valion Bio, Inc. (VBIO)'s trailing twelve month Return on Assets (ROA) is -101.40% as of 2026-06-30.
What is VBIO's ROIC (return on invested capital)?
Valion Bio, Inc. (VBIO)'s trailing twelve month Return on Invested Capital (ROIC) is -289.57% as of 2026-06-30.
What is VBIO's EV/EBITDA?
Valion Bio, Inc. (VBIO)'s trailing twelve month EV/EBITDA is -2.95x as of 2026-06-30.